Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm, basket trial

Kevin Kalinsky, Jennifer R. Diamond, Linda T. Vahdat, +13

Annals of Oncology

Abstract GS3-08: Alpelisib + fulvestrant for advanced breast cancer: Subgroup analyses from the phase III SOLAR-1 trial

Dejan Juric, Eva Ciruelos, Gábor Rubovszky, +17

Cancer Research

Breast OncologyPathologyOverall SurvivalTumor BiologyPre-clinical Pharmacology +14

Abstract P3-14-01: Phase Ib/II study of ribociclib and alpelisib and letrozole in ER+, HER2– breast cancer: Safety, preliminary efficacy and molecular analysis

Dejan Juric, Roohi Ismail‐Khan, Mario Campone, +13

Cancer Research

Breast OncologyCancer BiologyTumor BiologyCancer Cell BiologyAnti-cancer Agent +17

Abstract PD5-10: A first-in-human phase I study to evaluate the oral selective estrogen receptor degrader (SERD), GDC-0927, in postmenopausal women with estrogen receptor positive (ER+) HER2-negative metastatic breast cancer (BC)

MN Dickler, JA Perez Fidalgo, IA Mayer, +25

Cancer Research

Breast OncologyGdc-0927 ExposureEstrogen ReceptorGynecologyPharmacotherapy +18

A Phase Ib Trial of RAD001, an mTOR Inhibitor, with Weekly Cisplatin and Paclitaxel in Patients with HER2-Negative Metastatic Breast Cancer.

IA Mayer, Howard A. Burris, Johanna C. Bendell, +4

Cancer Research

Weekly CisplatinBasal-like Breast CancersBreast OncologyLuminal BMedicine +11

Abstract GS1-07: Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate, as ≥3rd-line therapeutic option for patients with relapsed/refractory metastatic triple-negative breast cancer (mTNBC): efficacy results

Aditya Bardia, Jennifer R. Diamond, Kevin Kalinsky, +13

Cancer Research

Abstract Gs1-07Aggressive CourseBreast OncologyImmunologyPathology +14

Abstract PD1-6: A randomized phase II neoadjuvant study of cisplatin, paclitaxel with or without everolimus (an mTOR inhibitor) in patients with stage II/III triple-negative breast cancer (TNBC)

IA Mayer, Bojana Jovanović, V Abramson, +13

Cancer Research

Surgical OncologyBreast OncologyCancer ManagementPathologyTumor Biology +15

Abstract GS6-05: Gain-of-function kinase library screen identifies FGFR1 amplification as a mechanism of resistance to antiestrogens and CDK4/6 inhibitors in ER+ breast cancer

Luigi Formisano, Yao Lu, VM Jansen, +17

Cancer Research

Breast OncologyOncologyMedicineReceptor Tyrosine KinasePharmacology +13

Abstract GS4-07: Race, ethnicity and clinical outcomes in hormone receptor-positive, HER2-negative, node-negative breast cancer: results from the TAILORx trial

Kathy S. Albain, RJ Gray, JA Sparano, +24

Cancer Research

Health Care DisparityBreast OncologyPatient SelectionGynecologyPopulation Health Sciences +24

Abstract OT3-2-07: Phase I study of ARN-810, a novel selective estrogen receptor degrader, in post-menopausal women with locally advanced or metastatic estrogen receptor positive breast cancer

IA Mayer, Aditya Bardia, MN Dickler, +10

Cancer Research

Breast OncologyGynecologyPharmacotherapyMolecular PharmacologyReceptor Activity +15